Managing Cardiovascular Risk in Patients with Low-Normal Thyroid Function

Understanding Low-Normal Thyroid Function

The American College of Cardiology recommends that patients with low-normal TSH (within reference range but at the lower end) should focus on monitoring rather than treatment, as thyroid hormone replacement is not indicated when thyroid function is truly normal, and overtreatment poses significant cardiovascular risks including atrial fibrillation, osteoporosis, and increased mortality 1, 2
TSH values between 0.4-2.5 mIU/L with normal free T4 represent normal thyroid function and do not constitute hypothyroidism, with a geometric mean TSH in disease-free populations of 1.4 mIU/L, making values in this range physiologically optimal 3
Low-normal TSH does not indicate a need for thyroid hormone supplementation, as it is within the normal range 3

The European Society of Cardiology states that when thyroid function is truly normal (TSH 0.4-4.5 mIU/L with normal free T4), no direct cardiovascular dysfunction occurs from the thyroid itself, and bradycardia, increased systemic vascular resistance, and diastolic dysfunction only manifest in actual hypothyroidism (elevated TSH with low or low-normal T4) 1, 2, 4
The American Heart Association recommends that patients with TSH 0.4-4.5 mIU/L with normal free T4 should manage cardiovascular risk factors (hypertension, dyslipidemia, diabetes) according to standard guidelines, without initiating levothyroxine 3, 5

The Endocrine Society suggests that for patients with confirmed normal thyroid function, screening for traditional cardiovascular risk factors (hypertension, dyslipidemia, diabetes, smoking) is necessary, and thyroid dysfunction is a precipitant of heart failure decompensation, but normal thyroid function is not a risk factor 5
For patients with subclinical hypothyroidism and cardiovascular disease, elderly patients (>70 years) with cardiac disease require a cautious approach, starting levothyroxine at 25-50 mcg/day if treatment is indicated, titrating slowly, and targeting TSH in the upper half of the reference range (2.5-5.0 mIU/L) initially to avoid cardiac complications 2, 3

Overtreatment with levothyroxine can lead to a 5-fold increased risk of atrial fibrillation in patients ≥45 years, increased risk of osteoporotic fractures, particularly in postmenopausal women, and potential increased cardiovascular mortality, as well as left ventricular hypertrophy and abnormal cardiac output 3

For patients with pre-existing cardiovascular disease, heart failure patients should have their thyroid function monitored, as hypothyroidism is a recognized precipitant of acute decompensated heart failure, and restoration of normal thyroid function may reverse abnormal cardiovascular function in true hypothyroidism, but normal thyroid function does not require intervention 5
Atrial fibrillation patients should maintain TSH >0.5 mIU/L to minimize arrhythmia risk, as overtreatment with levothyroxine significantly increases AF risk 3

For patients with normal thyroid function and cardiovascular disease, rechecking thyroid function is only necessary if symptoms develop (fatigue, weight changes, temperature intolerance), and no routine screening interval is required for asymptomatic patients with previously normal values 3
For patients on levothyroxine, monitoring TSH and free T4 every 6-8 weeks during dose titration, and once stable, monitoring annually or with symptom changes, with more frequent monitoring (every 2 weeks) for patients with atrial fibrillation or serious cardiac disease 3